Real-world biologic and apremilast treatment patterns in patients with psoriasis and psoriatic arthritis.
Dermatol Online J
; 27(9)2021 Sep 15.
Article
en En
| MEDLINE
| ID: mdl-34755976
ABSTRACT
PURPOSE:
Real-world treatment patterns among psoriasis patients with and without psoriatic arthritis (PsA) newly initiating treatment with a biologic or apremilast were assessed. PATIENTS ANDMETHODS:
MarketScan claims data from adults with psoriasis and ?1 new prescription for secukinumab, adalimumab, ustekinumab, etanercept, or apremilast from January 1, 2015, to August 31, 2018, were assessed for adherence, switching, and combination therapy by index medication and PsA diagnosis.RESULTS:
At treatment initiation, 22.0%-45.7% of patients had PsA. Over 24 months, discontinuation rates were high (34.4%-54.6%) overall and higher in patients with versus without PsA (all P<0.05 except secukinumab). Adherence was poor (16.8%-34.8%); switching and combination therapy were common.CONCLUSION:
Treatment patterns varied, with better outcomes in PsA patients receiving anti-tumor necrosis factor versus anti-IL17/IL12/23 agents.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Psoriasis
/
Talidomida
/
Artritis Psoriásica
/
Anticuerpos Monoclonales Humanizados
Tipo de estudio:
Observational_studies
/
Risk_factors_studies
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Dermatol Online J
Asunto de la revista:
DERMATOLOGIA
Año:
2021
Tipo del documento:
Article
País de afiliación:
Nueva Caledonia